AI English summary of an SEC filing — figures as filed
Zimmer Biomet ZBHZimmer Biomet said it is filing this 8-K to recast parts of the financial information and related disclosures in its 2023 Form 10-K, after the segment operating profit measures reviewed by its chief operating decision maker were revised in the quarter ended March 31, 2024.
Key points
AI summaryZimmer Biomet said it is filing this 8-K to recast parts of the financial information and related disclosures in its 2023 Form 10-K, after the segment operating profit measures reviewed by its chief operating decision maker were revised in the quarter ended March 31, 2024.
The company said certain product category headquarter costs, mainly research and development and marketing, previously in its Americas operating segment were reclassified to Corporate items, and certain support function costs were also moved there. It said its operating segments and reportable segments did not change.
The company said it recast Part II, Item 7 (MD&A) and Item 8 (Financial Statements and Supplementary Data) of its 2023 Form 10-K in Exhibit 99.1, and that it did not update other information apart from the changes to segment operating profit measures. It said the filing is not an amendment or restatement of that report.
The company disclosed that recast full-year 2023 segment operating profit was $2,487.1 million for Americas (53.8% of net sales), $538.2 million for EMEA (33.8%) and $432.3 million for Asia Pacific (36.7%).
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Background of the 2023 Form 10-K recast filing
Zimmer Biomet said it is filing this 8-K to recast parts of the financial information and related disclosures in its 2023 Form 10-K, after the segment operating profit measures reviewed by its chief operating decision maker were revised in the quarter ended March 31, 2024.
Source · Based on the filing body and exhibits
Costs moved to Corporate items and segment classification
The company said certain product category headquarter costs, mainly research and development and marketing, previously in its Americas operating segment were reclassified to Corporate items, and certain support function costs were also moved there. It said its operating segments and reportable segments did not change.
Source · Based on the filing body and exhibits
Recast items and scope
The company said it recast Part II, Item 7 (MD&A) and Item 8 (Financial Statements and Supplementary Data) of its 2023 Form 10-K in Exhibit 99.1, and that it did not update other information apart from the changes to segment operating profit measures. It said the filing is not an amendment or restatement of that report.
Source · Based on the filing body and exhibits
Recast annual segment operating profit
The company disclosed that recast full-year 2023 segment operating profit was $2,487.1 million for Americas (53.8% of net sales), $538.2 million for EMEA (33.8%) and $432.3 million for Asia Pacific (36.7%).
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…